Leerink Partners Report Names Carterra a Core Enabler of the $7B "Lab-in-the-Loop" Antibody Discovery Market
New research on AI-driven biologics discovery identifies Carterra's high-throughput SPR platforms as central to the Lab-in-the-Loop (LitL) workflow reshaping drug discovery, with Twist Bioscience and Adaptyv Bio pointing to surging demand for Carterra technology
Carterra®, a leading provider of high-throughput surface plasmon resonance (HT-SPR) platforms for antibody and small molecule discovery, today highlighted new research from Leerink Partners identifying Carterra as a key enabling technology in the fast-growing market for AI-driven biologics drug discovery.
In a report published July 16, 2026, titled "Lab-in-the-Loop: AI Rewires Antibody Discovery, Unlocking a $7B LST Opportunity," Leerink Partners analyst Puneet Souda and team estimate a total addressable market of roughly $7 billion in life science tools demand tied to AI-enabled antibody discovery — including a $4 billion biologics drug discovery layer, of which an estimated $1.3 billion is currently outsourced to service providers. The report describes "Lab-in-the-Loop," or LitL, as the emerging paradigm in which AI models propose candidate antibody sequences, wet lab experiments test them, and the resulting data feed back to sharpen each subsequent round of design — turning what was once a slow, serial discovery process into a faster, guided one.
